Empaveli

Chemical Namepegcetacoplan
Dosage FormInjection (subcutaneous; 1,080 mg/20 mL (54 mg/mL))
Drug ClassInhibitors
SystemBlood
CompanyApellis Pharmaceuticals
Approval Year2021

Indication

  • For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Last updated on 3/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Empaveli (pegcetacoplan) Prescribing Information.2021Apellis Pharmaceuticals, Inc., Waltham, MA
Document TitleYearSource
Assessment report: aspaveli. 2021EMA